黑龙江医药
黑龍江醫藥
흑룡강의약
HEILONGJIANG MEDICAL JOURNAL
2014年
6期
1301-1303,1304
,共4页
支气管哮喘%超氧化物歧化酶(SOD)%血管活性肠肽(VIP)%肿瘤坏死因子-α(TNF-α)%瘦素(Lep)%诊断%随访
支氣管哮喘%超氧化物歧化酶(SOD)%血管活性腸肽(VIP)%腫瘤壞死因子-α(TNF-α)%瘦素(Lep)%診斷%隨訪
지기관효천%초양화물기화매(SOD)%혈관활성장태(VIP)%종류배사인자-α(TNF-α)%수소(Lep)%진단%수방
bronchial asthma%superoxide dismutase(SOD)%Vasoactive intestinal peptide (VIP) tumor necrosis factor-α(TNF-α)%Leptin(Lep) diagnosis%following
目的：为了探讨支气管哮喘患儿治疗前后血清SOD、VIP、TNF-α和Lep水平变化的临床意义。方法：放射免疫分析和酶免疫分析测定了87例支气管哮喘患儿和60例正常儿的血清SOD、VIP、TNF-α和Lep水平并进行了比较性分析。结果：在治疗前，87例支气管哮喘患儿血清SOD和VIP水平较之60例正常儿明显降低（tSOD=3.018，tVIP=3.146，P均<0.01），而血清TNF-α和Lep水平明显增高（tTNF-α=4.637，P<0.001，tLep=3.261，P<0.01）。在治疗后，87例支气管哮喘患儿血清SOD和VIP水平恢复至正常，较之正常儿无明显的差异（tSOD=1.586，tVIP=1.563，P均>0.05），而血清TNF-α和Lep水平明显降低，但相较之正常儿增高（tTNF-α=2.103，tLep=2.243，Pall<0.05）。结论：SOD和VIP水平的测定是诊断支气管哮喘患儿的良好指标，而且在糖皮质激素综合治疗后，可以进行随访和疗效的考核。
目的：為瞭探討支氣管哮喘患兒治療前後血清SOD、VIP、TNF-α和Lep水平變化的臨床意義。方法：放射免疫分析和酶免疫分析測定瞭87例支氣管哮喘患兒和60例正常兒的血清SOD、VIP、TNF-α和Lep水平併進行瞭比較性分析。結果：在治療前，87例支氣管哮喘患兒血清SOD和VIP水平較之60例正常兒明顯降低（tSOD=3.018，tVIP=3.146，P均<0.01），而血清TNF-α和Lep水平明顯增高（tTNF-α=4.637，P<0.001，tLep=3.261，P<0.01）。在治療後，87例支氣管哮喘患兒血清SOD和VIP水平恢複至正常，較之正常兒無明顯的差異（tSOD=1.586，tVIP=1.563，P均>0.05），而血清TNF-α和Lep水平明顯降低，但相較之正常兒增高（tTNF-α=2.103，tLep=2.243，Pall<0.05）。結論：SOD和VIP水平的測定是診斷支氣管哮喘患兒的良好指標，而且在糖皮質激素綜閤治療後，可以進行隨訪和療效的攷覈。
목적：위료탐토지기관효천환인치료전후혈청SOD、VIP、TNF-α화Lep수평변화적림상의의。방법：방사면역분석화매면역분석측정료87례지기관효천환인화60례정상인적혈청SOD、VIP、TNF-α화Lep수평병진행료비교성분석。결과：재치료전，87례지기관효천환인혈청SOD화VIP수평교지60례정상인명현강저（tSOD=3.018，tVIP=3.146，P균<0.01），이혈청TNF-α화Lep수평명현증고（tTNF-α=4.637，P<0.001，tLep=3.261，P<0.01）。재치료후，87례지기관효천환인혈청SOD화VIP수평회복지정상，교지정상인무명현적차이（tSOD=1.586，tVIP=1.563，P균>0.05），이혈청TNF-α화Lep수평명현강저，단상교지정상인증고（tTNF-α=2.103，tLep=2.243，Pall<0.05）。결론：SOD화VIP수평적측정시진단지기관효천환인적량호지표，이차재당피질격소종합치료후，가이진행수방화료효적고핵。
Objective:To explore the clinical significance of determining Changes of serum SOD、VIP、TNF-αand Lep levels in before and after therapy in pediatric patients with Bronchial asthma. Methods:the serum SOD、VIP、TNF-αand Lep levels were de-termined in 87 pediatrics patients with bronchial asthma and 60 controls by radioimmunoassay and enzyme immunoassay as well as done study compared. Results:In before therapy, the serum SOD and VIP levels in 87 pediatrics patients with bronchial asthma were significantly lower than in those of to controls(tSOD=3.018,tVIP=3.146,Pall<0.01),the serum TNF-αand Lep levels in 87 pediatrics patients with bronchial asthma significantly higher than in those of 60 controls(tTNF-α=4.637,P<0.001,tLep=3.261,P<0.01). In af-ter therapy, the serum SOD and VIP levels in 87 pediatrics patients with bronchial asthma were discovery to normal levels and not much different than in those of 60 controls(tSOD=1.586,tVIP=1.563,Pall>0.05),but the serum TNF-αand Lep levels were signifi-cantly decreased and still higher than in those of 60 controls(tTNF-α=2.103,tLep=2.243,Pall<0.05). Conclusion:The serum SOD and VIP levels were a valueable index for diagnosis of pediatrics patients with bronchial asthma and after inhalation of Glucocorticoi-ols therapy, could be following and test effect of therapy.
